Reviva Pharmaceuticals Holdings Inc. Stock

$0.37

1.92%

Nasdaq, Jul 07, 10:20 pm CET

ISIN

US76152G1004

Symbol

RVPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Reviva Pharmaceuticals Holdings Inc. Stock price

$0.37

-10.37 96.58% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

+0.01 1.92%

ISIN

US76152G1004

Symbol

RVPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$24.5m

Enterprise Value

$19.4m

Net debt

positive

Cash

$5.3m

Shares outstanding

46.7m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

5.2%

Return on Equity

-3,680.1%

ROCE

664.0%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

- | -

EBIT

$-29.4m | $-36.0m

Net Income

$-28.9m | $-24.1m

Free Cash Flow

$-30.0m

EPS

$-0.6

FCF per Share

$-0.6

Short interest

8.5%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Reviva Pharmaceuticals Holdings Inc. Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a Reviva Pharmaceuticals Holdings Inc. forecast:

11x Buy

92%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a Reviva Pharmaceuticals Holdings Inc. forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Reviva Pharmaceuticals Holdings Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	8.18 8.18	6% 6% -
- Research and Development Expense	21 21	34% 34% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-29 -29	28% 28% -
Net Profit	-29 -29	28% 28% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Reviva Pharmaceuticals Holdings Inc. Stock News

Neutral

GlobeNewsWire

●

12 days ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering wit...

Neutral

GlobeNewsWire

●

12 days ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or com...

Neutral

GlobeNewsWire

●

about one month ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO ...

More Reviva Pharmaceuticals Holdings Inc. News

Company Profile

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded on December 11, 2020 and is headquartered in Cupertino, CA.

Head office	United States
CEO	Laxminarayan Bhat
Employees	15
Founded	2020
Website	revivapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now